<SEC-DOCUMENT>0001140361-20-017612.txt : 20200806
<SEC-HEADER>0001140361-20-017612.hdr.sgml : 20200806
<ACCEPTANCE-DATETIME>20200806073520
ACCESSION NUMBER:		0001140361-20-017612
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200806
FILED AS OF DATE:		20200806
DATE AS OF CHANGE:		20200806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			InflaRx N.V.
		CENTRAL INDEX KEY:			0001708688
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38283
		FILM NUMBER:		201079842

	BUSINESS ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745
		BUSINESS PHONE:		49 3641 508180

	MAIL ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Fireman B.V.
		DATE OF NAME CHANGE:	20170606
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>brhc10014139_6k.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Sabres09!
         Document created using EDGARfilings PROfile 7.1.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <div style="text-align: center; font-weight: bold;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
      <div style="text-align: center; font-weight: bold;">
        <div style="font-size: 14pt; font-weight: bold;">UNITED STATES</div>
        <div style="font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
        <div style="font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      </div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; font-weight: bold;">
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 30%; color: #000000;"></div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM 6-K</div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; font-weight: bold;">
        <div style="font-weight: bold;">
          <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 30%; color: #000000;"></div>
        <div style="font-weight: bold;">&#160;</div>
      </div>
      <div style="text-align: center; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO RULE 13A-16 OR 15D-16 UNDER</div>
      <div style="text-align: center; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">For the month of August 2020</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Commission File Number: 001-38283</div>
      <div>
        <div style="text-align: center; font-weight: bold;"> <br>
        </div>
        <div style="text-align: center; font-weight: bold;">
          <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 35%; color: #000000;"></div>
        <div style="text-align: center; font-weight: bold;">&#160;</div>
      </div>
      <div style="text-align: center; font-size: 24pt; font-weight: bold;">InflaRx N.V.</div>
      <div>&#160;</div>
      <div style="text-align: center; color: #000000;">(Translation of registrant's name into English)</div>
      <div><br>
      </div>
      <div>
        <div style="text-align: center; font-weight: bold;">
          <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 35%; color: #000000;"></div>
        <div style="text-align: center; font-weight: bold;">&#160;</div>
      </div>
      <div style="text-align: center; font-weight: bold;">Winzerlaer Str. 2</div>
      <div style="text-align: center; font-weight: bold;">07745 Jena, Germany</div>
      <div style="text-align: center;">(Address of principal executive office)</div>
      <br>
      <div style="text-align: center; font-weight: bold;">
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 35%; color: #000000;"></div>
      <div style="text-align: center; font-weight: bold;">&#160;</div>
      <div>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
      <div> <br>
      </div>
      <div><a name="Check1"></a></div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z1f29f3ae7df04003930b2017d27a4b37">

            <tr>
              <td style="width: 12%;">Form 20-F &#9746;</td>
              <td style="width: 88%;">Form 40-F &#9744;</td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
      <div>&#160;</div>
      <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
      <div>&#160;</div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">INFLARX N.V.</div>
      <div>&#160;</div>
      <div style="text-align: justify;">On August 6, 2020, InflaRx N.V. issued a press release. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%3%%%-->
      <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
      <div>&#160;</div>
      <div>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
        duly authorized.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="ze22d33a3d02a4ffcba2ce893e6104b31" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="3">
              <div style="font-weight: bold;">INFLARX N.V.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="3">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div>Date: August 6, 2020</div>
            </td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">By:</td>
            <td style="width: 2%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">/s/</td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid black;">
              <div>Niels Riedemann</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top; width: 6%;">
              <div>Name:</div>
            </td>
            <td style="width: 44%; vertical-align: top;">
              <div>Niels Riedemann</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top; width: 6%;">
              <div>Title:</div>
            </td>
            <td style="width: 44%; vertical-align: top;">
              <div>Chief Executive Officer</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z696da12f0fed46dd8a0b6ea9d6518117" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 9%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-weight: bold;">
                <div>Exhibit No.</div>
              </div>
            </td>
            <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; font-weight: bold;" colspan="1">&#160;</td>
            <td style="width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-weight: bold;">
                <div>Description</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 9%; vertical-align: top;">
              <div><a href="brhc10014139_ex99-1.htm">99.1</a></div>
            </td>
            <td style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 90%; vertical-align: bottom;">
              <div>Press Release, dated August 6, 2020</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div>
        <div style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber"> <br>
          </font></div>
        <div style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font></div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>brhc10014139_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Sabres09!
         Document created using EDGARfilings PROfile 7.1.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="color: rgb(0, 0, 0);">
  </font>
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0);"> </div>
      <div style="text-align: right; color: rgb(0, 0, 0);"><font style="font-weight: bold;"> Exhibit 99.1</font><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0);"> <br>
      </div>
      <div style="color: rgb(0, 0, 0);"> <img src="image00002.jpg"></div>
      <div style="text-align: center; color: rgb(0, 0, 0);"> <br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0);">InflaRx to Present at Upcoming Virtual Investor Events</div>
      <div style="color: rgb(0, 0, 0);"><br>
      </div>
      <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Jena, Germany, August 6, 2020 </font><font style="color: rgb(0, 0, 0);">&#8211; InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at several upcoming virtual investor events in
          August and September as follows:</font></div>
      <div style="color: rgb(0, 0, 0);">&#160;</div>
      <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">BTIG Virtual Biotechnology Conference:</font><font style="color: rgb(0, 0, 0);">&#160;<font style="font-weight: bold;">August 10</font><sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup><font style="font-weight: bold;"> &#8211; 11</font><sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup></font></div>
      <div style="color: rgb(0, 0, 0);">&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">A BTIG analyst will host a fireside chat with Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, to discuss the
        Company&#8217;s pipeline and upcoming catalysts on <font style="font-weight: bold;">Monday, August 10</font><sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup><font style="font-weight: bold;"> at 12:30pm EST. </font>The Company will also hold virtual 1X1 meetings.</div>
      <div style="color: rgb(0, 0, 0);">&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">A <u>live webcast</u> of the fireside chat will be provided on the InflaRx website in the Investors section under Events &amp; Presentations. A replay will be available following the live event.</div>
      <div style="color: rgb(0, 0, 0);">&#160;</div>
      <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">H.C. Wainwright Annual Global Investment Conference:</font><font style="color: rgb(0, 0, 0);">&#160;<font style="font-weight: bold;">September 14</font><sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup><font style="font-weight: bold;"> &#8211; 16</font><sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup></font></div>
      <div style="color: rgb(0, 0, 0);">&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">The Company will give a presentation and conduct virtual 1X1 meetings.</div>
      <div style="color: rgb(0, 0, 0);">&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">A live webcast of the Company&#8217;s presentation will be provided on
          the InflaRx website in the Investors section under Events &amp; Presentations.</div>
      <div style="color: rgb(0, 0, 0);">&#160;</div>
      <div style="text-align: justify; font-weight: bold; color: rgb(0, 0, 0);">Oppenheimer Fall Healthcare Life Sciences &amp; MedTech Summit: September 21<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> &#8211; 23<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup></div>
      <div style="color: rgb(0, 0, 0);">&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">The Company will give a presentation and conduct virtual 1X1 meetings.</div>
      <div style="color: rgb(0, 0, 0);">&#160;</div>
      <div style="text-align: justify; font-weight: bold; color: rgb(0, 0, 0);">About IFX-1:</div>
      <div style="color: rgb(0, 0, 0);">&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">IFX-1 is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological
        activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the
        cleavage of C5. IFX-1 has been demonstrated to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key &#8220;amplifier&#8221; of this response in pre-clinical studies. IFX-1 is believed to be the first monoclonal
        anti-C5a antibody introduced into clinical development. Approximately 300 people have been treated with IFX-1 in clinical trials, and the antibody has been shown to be well tolerated. IFX-1 is currently being developed for various indications,
        including Hidradenitis Suppurativa, ANCA-associated vasculitis, Pyoderma Gangraenosum and COVID-19 pneumonia.</div>
      <div style="color: rgb(0, 0, 0);">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; font-weight: bold; color: rgb(0, 0, 0);"> <img src="image00002.jpg"></div>
      <div style="text-align: justify; font-weight: bold; color: rgb(0, 0, 0);">About InflaRx N.V.:</div>
      <div style="color: rgb(0, 0, 0);">&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover
        and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the
        group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information please visit <u>www.inflarx.com</u>.</div>
      <div style="color: rgb(0, 0, 0);">&#160;</div>
      <div style="font-weight: bold; color: rgb(0, 0, 0);">Contacts:</div>
      <div style="font-weight: bold; color: rgb(0, 0, 0);"> <br>
      </div>
      <div style="font-weight: bold; color: rgb(0, 0, 0);">InflaRx N.V.</div>
      <div style="color: rgb(0, 0, 0);">Jordan Zwick &#8211; Global Head of Business Development &amp; Corporate Strategy</div>
      <div style="color: rgb(0, 0, 0);">Email: jordan.zwick[at]inflarx.de</div>
      <div style="color: rgb(0, 0, 0);">Tel: +1 917-338-6523</div>
      <div style="color: rgb(0, 0, 0);">&#160;</div>
      <div style="font-weight: bold; color: rgb(0, 0, 0);">MC Services AG</div>
      <div style="color: rgb(0, 0, 0);">Katja Arnold, Laurie Doyle, Andreas Jungfer</div>
      <div style="color: rgb(0, 0, 0);">Email: inflarx[at]mc-services.eu</div>
      <div style="color: rgb(0, 0, 0);">Europe: +49 89-210 2280</div>
      <div style="color: rgb(0, 0, 0);">US: +1-339-832-0752</div>
      <div style="color: rgb(0, 0, 0);"><br>
      </div>
      <div style="color: rgb(0, 0, 0);">FORWARD-LOOKING STATEMENTS</div>
      <div style="color: rgb(0, 0, 0);">&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking
        statements, which are often indicated by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; and similar expressions.
        Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and
        planned preclinical development and clinical trials; the impact of the COVID-19 pandemic on the Company; the timing&#160; of and our ability to commence and conduct clinical trials; potential results from current or potential future collaborations; our
        ability to make regulatory filings, obtain positive guidance from regulators, and obtain and maintain regulatory approvals for our product candidates; our intellectual property position; our ability to develop commercial functions; expectations
        regarding clinical trial data; our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies; the industry in which we operate; the trends that may affect the industry or us and the
        risks, uncertainties and other factors described under the heading &#8220;Risk Factors&#8221; in InflaRx&#8217;s periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and
        unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking
        statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes
        available in the future, except as required by law.</div>
      <div style="text-align: justify; color: rgb(0, 0, 0);"> <br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);"> <br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
  <font style="color: rgb(0, 0, 0);">
  </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !$ + # 2(  A$! Q$!_\0
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MW]Q<R;"8PX"<$DYVX/ ]:[>OFK]FW13>>+;K577]UI\!53C_ ):2<#_QT/\
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)HH **** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
